文献速递消化系统肿瘤泌尿男性生殖肿瘤妇科肿瘤

盆腔放疗后第二原发直肠癌风险增加

Increased risk for second primary rectal cancer after pelvic radiation therapy.
PubMed 文献 · Eur J Cancer · 2019-11-22

基于荷兰癌症登记1989–2007年192,658例盆腔原发肿瘤患者数据,分析盆腔放疗与第二原发直肠癌的关联。中位间隔6年时1369例发生直肠癌,放疗后总体风险升高(SHR 1.72,95%CI 1.55–1.91),前列腺癌和子宫内膜癌放疗后风险增加,膀胱癌放疗后风险降低,两组直肠癌患者生存无差异。

要点

  • 盆腔放疗后第二原发直肠癌总体风险升高,SHR 1.72(95%CI 1.55–1.91)。
  • 前列腺癌放疗后风险增加(SHR 1.89),子宫内膜癌放疗后风险增加(SHR 1.50)。
  • 膀胱癌放疗后直肠癌风险降低(SHR 0.67),既往放疗与否生存无差异。

核心结论

  • 既往盆腔肿瘤接受放疗的患者第二原发直肠癌风险增加,风险程度中等,在前列腺癌和子宫内膜癌放疗患者中更明显。

研究设计与样本

  • 基于荷兰癌症登记的人群回顾性队列研究,纳入1989–2007年治疗的盆腔原发肿瘤患者192,658例,排除多于一种盆腔肿瘤者,其中62,630例接受放疗。

主要发现

  • 中位间隔6年(范围0–24)时1369例发生直肠癌,放疗后总体直肠癌风险升高(SHR 1.72,95%CI 1.55–1.91)。
  • 前列腺癌放疗后直肠癌风险升高(SHR 1.89,95%CI 1.66–2.16),子宫内膜癌放疗后风险升高(SHR 1.50,95%CI 1.13–2.00)。
  • 膀胱癌放疗后直肠癌风险降低(SHR 0.67,95%CI 0.47–0.94)。
  • 既往放疗与未放疗的直肠癌患者生存无差异(HR 0.94,95%CI 0.79–1.11)。

临床怎么用

  • 对盆腔肿瘤放疗后长期存活者,尤其前列腺癌和子宫内膜癌患者,应关注第二原发直肠癌风险并进行相应随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to analyse the association between pelvic radiation therapy (RT) and the development of rectal cancer as a second primary cancer. METHODS: Data on patients treated for a primary pelvic cancer between 1989 and 2007 were retrieved from the population-based Netherlands Cancer Registry. Patients treated for more than one pelvic cancer were excluded. To estimate the cumulative incidence of rectal cancer, Fine and Gray's competing risk model was used with death as a competing event. Survival was calculated using multivariable Cox regression. RESULTS: A total of 192,658 patients were included, of which 62,630 patients were treated with RT for their pelvic cancer. Primary tumours were located in the prostate (50.1%), bladder (19.2%), endometrium (13.9%), ovaries (10.0%), cervix (6.4%) and vagina (0.4%). At a median interval of 6 years (range 0-24), 1369 patients developed a rectal cancer. Overall, the risk for rectal cancer was increased in patients who underwent RT for the previous pelvic cancer (subhazard ratio [SHR]: 1.72, 95% confidence interval [CI]: 1.55-1.91). Analysis for each tumour location specifically showed an increased risk in patients who received RT for prostate (SHR: 1.89, 95% CI: 1.66-2.16) or endometrial cancer (SHR: 1.50, 95% CI: 1.13-2.00). A protective effect of RT was observed for patients with bladder cancer (SHR 0.67, 95% CI: 0.47-0.94). There was no survival difference between patients with rectal cancer with or without previous RT (hazard ratio: 0.94, 95% CI: 0.79-1.11). CONCLUSIONS: Patients who received RT for a previous pelvic cancer were at increased risk for rectal cancer. The risk was modest and pronounced in patients receiving RT for prostate and endometrial cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rombouts AJM, Hugen N, Elferink MAG, et al. Increased risk for second primary rectal cancer after pelvic radiation therapy. Eur J Cancer. 2019. PMID: 31765989. doi:10.1016/j.ejca.2019.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。